Literature DB >> 10899441

The role of complement in Alzheimer's disease pathology.

M R Emmerling1, M D Watson, C A Raby, K Spiegel.   

Abstract

Complement proteins are integral components of amyloid plaques and cerebral vascular amyloid in Alzheimer brains. They can be found at the earliest stages of amyloid deposition and their activation coincides with the clinical expression of Alzheimer's dementia. This review will examine the origins of complement in the brain and the role of beta-amyloid peptide (Abeta) in complement activation in Alzheimer's disease, an event that might serve as a nidus of chronic inflammation. Pharmacology therapies that may serve to inhibit Abeta-mediated complement activation will also be discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10899441     DOI: 10.1016/s0925-4439(00)00042-9

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  25 in total

Review 1.  Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature.

Authors:  Tony Wyss-Coray; Joseph Rogers
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

2.  Brain Atrophy, Anti-Smooth Muscle Antibody and Cognitive Impairment: An Association Study.

Authors:  Paroni Giulia; Lauriola Michele; Fontana Andrea; D'Onofrio Grazia; Ciccone Filomena; Paris Francesco; Cascavilla Leandro; Urbano Maria; Gravina Carolina; Copetti Massimiliano; Greco Antonio
Journal:  Aging Dis       Date:  2015-11-24       Impact factor: 6.745

Review 3.  Amyloidosis associated with cerebral amyloid angiopathy: cell signaling pathways elicited in cerebral endothelial cells.

Authors:  Jorge Ghiso; Silvia Fossati; Agueda Rostagno
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 4.  Phagocytic clearance in neurodegeneration.

Authors:  Jennifer D Sokolowski; James W Mandell
Journal:  Am J Pathol       Date:  2011-04       Impact factor: 4.307

5.  Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB.

Authors:  Kazuhiro Ohmi; David S Greenberg; Kavitha S Rajavel; Sergey Ryazantsev; Hong Hua Li; Elizabeth F Neufeld
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-07       Impact factor: 11.205

Review 6.  Leptin: a novel therapeutic strategy for Alzheimer's disease.

Authors:  Nikolaos Tezapsidis; Jane M Johnston; Mark A Smith; J Wesson Ashford; Gemma Casadesus; Nikolaos K Robakis; Benjamin Wolozin; George Perry; Xiongwei Zhu; Steven J Greco; Sraboni Sarkar
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

7.  Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice.

Authors:  Tony Wyss-Coray; Fengrong Yan; Amy Hsiu-Ti Lin; John D Lambris; Jessy J Alexander; Richard J Quigg; Eliezer Masliah
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-15       Impact factor: 11.205

8.  Implication of complement system and its regulators in Alzheimer's disease.

Authors:  Martin V Kolev; Marieta M Ruseva; Claire L Harris; B Paul Morgan; Rossen M Donev
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

9.  Enhanced insight into the autoimmune component of glaucoma: IgG autoantibody accumulation and pro-inflammatory conditions in human glaucomatous retina.

Authors:  Oliver W Gramlich; Sabine Beck; Nadine von Thun Und Hohenstein-Blaul; Nils Boehm; Anika Ziegler; Jan M Vetter; Norbert Pfeiffer; Franz H Grus
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

10.  Deletion of Crry, the murine ortholog of the sporadic Alzheimer's disease risk gene CR1, impacts tau phosphorylation and brain CFH.

Authors:  R Killick; T R Hughes; B P Morgan; S Lovestone
Journal:  Neurosci Lett       Date:  2012-11-12       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.